

Response Khan S P Khan, et al. (J Pak Med Assoc. 74: 1654-1658, September 2024)

Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus

Museera Zahid¹, Samia Perwaiz Khan², Sana Ershad³, Safia Izhar⁴, Rizwana Warraich⁵, Ali Asgha⁶

Thank you for your comments on our paper. As we have mentioned in our article the initial total sample size of participants in this study diagnosed with NAFLD by performing ultrasound liver was 200, out of total number of these 154 were diagnosed as NAFLD and T2DM and 46 with fatty liver changes only. Thus, showing a high level of association of NAFLD with TY2DM. They were divided into four treatment groups. Post-treatment improvement

.....
¹Medicare Cardiac and General Hospital, Sohail University, Karachi, Pakistan, ^{2,3}Department of Pharmacology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan; ⁴Department of Radiology, Medicare Cardiac and General Hospital, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan; ⁵Department of Molecular Biology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan; ⁶Department of Endocrinology, Medicare Cardiac and General Hospital, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan.

Correspondence: Samia Perwaiz Khan. **Email:** samiaphk@gmail.com

ORCID ID: 0000-0003-3154-1785

was reported in forty eight patients, participants of Group A on (Empagliflozin + metformin) twenty (42%) improved, by reduced HBA1c levels, BMI and SGPT/SGOT levels along with improvement in fatty liver changes. We do acknowledge that small sample size in follow-up being a limitation of our study. Larger Studies are the need of the day and also our intention.

References

1. Hooshmand Gharabagh L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Clin Res Hepatol Gastroenterol* 2024;48:102279. doi: 10.1016/j.clinre.2023.102279.
2. Esmaeili A, Pourahmad Azar R, Mohammad Hosseini Azar M, Hooshmand Gharabagh L. Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open-label, single-center, pilot clinical trial. *J Gen Fam Med* 2024;25:351-7. doi: 10.1002/jgf2.723.
3. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. *Diabetes Metab* 2019;45:213-23. doi: 10.1016/j.diabet.2019.01.008.